Flot.bio x Philip Hemme Flot.bio

We’re in San Sebastián 🇪🇸 with Naveed Siddiqi of one of Europe's largest biotech investors, Novo Holdings.



We talked about how things really are in European biotech at the moment. We also talked about his upbringing as a second-generation immigrant in the UK and the importance of diversity. I’ve known him since he was a partner at Andera. He is a sharp investor, but also very friendly and open.



💎 ABOUT THE SPEAKER



Naveed has been a part of Novo Holdings since 2019 and splits his time between London and Copenhagen. He has over 25 years of experience in life science venture investment as well as investment banking. Before joining Novo Holdings he was a partner at Andera Partners, a venture capital and growth equity firm with over 2 billion euros to focus on life science investment.



🔗 LINKS MENTIONED



-Novo leads Q4 2023 as Top Investor - Oppenheimer: https://drive.google.com/file/d/1b-t2Ba-fnHdyJhIq4j-d7dSCk7Vj65bw/view?usp=sharing
- Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group - https://amolytpharma.com/2023/01/06/amolyt-pharma-announces-138-million-series-c-financing-led-by-sofinnova-partners-and-co-led-by-intermediate-capital-group/
- AstraZeneca inks $800M buyout of French biotech to snag phase 3 rare disease drug - https://www.fiercebiotech.com/biotech/astrazeneca-inks-800m-buyout-snag-phase-3-rare-disease-drug
- Novo-backed Amolyt Pharma snags $80M series B for endocrine pipeline - https://www.fiercebiotech.com/biotech/novo-backed-amolyt-pharma-snags-80m-series-b-for-endocrine-pipeline



📜 TRANSCRIPT



Read the full transcript here: https://flot.bio/episode/naveed-siddiqi-novo-holdings/



🫶 FOLLOW US



- Newsletter: http://eepurl.com/h_fnmH


- LinkedIn: https://www.linkedin.com/company/flot-bio/


- X (Twitter): https://x.com/FlotBio



🎙️ ABOUT FLOT.BIO



Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.



⭐️ SPONSORSHIP



Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!



🙏 LIKE/FOLLOW/REVIEW



Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.



⏰ TIMESTAMPS


[00:00:00] Intro


[00:02:09] European biotech


[00:18:06] Billion dollar exits


[00:37:17] Diversity


[00:45:04] Thanks for listening

We’re in Hannover 🇩🇪 with the founder and CEO of Cardior, Claudia Ulbrich



We talked about Cardior’s recent €1B exit to Novo Nordisk. We also talk about miRNA and Cardiovascular, and why she earned the funny nickname “Frau Biotech”.



💎 ABOUT THE SPEAKER


Claudia has been founding biotechs since the ’90s. She founded her first biotech company, LipoNova AG in 1998 and went on to co-found many more, including Cardior Pharmaceuticals. During her time she has launched and brought public a cancer vaccine company, helped see through a multi-million dollar deal of over €20M, and much more.



🔗 LINKS MENTIONED


- Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=167038



📜 TRANSCRIPT


Read the full transcript here:



🫶 FOLLOW US


- Newsletter: http://eepurl.com/h_fnmH


- LinkedIn: https://www.linkedin.com/company/flot-bio/


- X: https://x.com/FlotBio



🎙️ ABOUT FLOT.BIO


Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.



⭐️ SPONSORSHIP


Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!



🙏 LIKE/FOLLOW/REVIEW


Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.



⏰ TIMESTAMPS



[00:00:00] Intro

[00:01:47] Novo Nordisk deal

[00:10:19] Results from heart disease phase1

[00:19:55] MicroRNA

[00:26:42] The history of Cardior

[00:41:49] Working with Centerview

[00:45:17] Frau Biotech

[00:53:57] Thanks for listening

We’re super privileged to chat online with Bahija Jallal, the CEO of Immunocore. Immunocore is the largest biotech in the UK and the 5th largest in Europe with a market cap of just over 3 billion dollars. We talk about how Immunocore has helped thousands of cancer patients and has become a commercial biotech. We also talk about why she thinks gender and race diversity are a business case and how AI is changing protein and biologics engineering.

💎 ABOUT THE SPEAKER
I’ve “known” Bahija for over 10 years, after reading her profile in a student pharma magazine when I was studying bioengineering in France. At that time, she was head of MedImmune and SVP R&D at AstraZeneca. Now as the CEO of Immunocore, with their pioneering T cell receptor platform, she has helped to bring incredible treatments for cancer patients to market.

🔗 LINKS MENTIONED

- Bahija on the Breakthrough Labs podcast - https://open.spotify.com/episode/2X4xedUdJid9GeioRSkCrP?si=39d8c7511aab443f
- Immatics builds on its PRAME Success (and competes with Immunocore) - [OncologyPipeline.com](https://www.oncologypipeline.com/apexonco/immatics-builds-its-prame-success)

📜 TRANSCRIPT
Read the full transcript here:

🫶 FOLLOW US
- Newsletter: http://eepurl.com/h_fnmH
- LinkedIn: https://www.linkedin.com/company/flot-bio/
- X (Twitter): https://x.com/FlotBio

🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.

⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!

🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

⏰ TIMESTAMPS

[00:00:00] Intro

[00:00:34] Welcome

[00:01:46] Immunocore’s life-changing cancer drug

[00:07:40] Commercializing Immunocore

[00:13:46] Explaining the TCR technology

[00:20:40] Targeting tumors with PRAME

[00:23:26] Immunocore now and then

[00:35:37] Why Bahija chose Immunocore

[00:40:22] Top lessons from Bahija Jallal

[00:45:48] How is risk appetite connected to innovation?

[00:49:10] Diversity in biotech

[01:00:59] Biological innovation

[01:05:49] AI in protein engineering optimization

[01:14:42] Thanks for listening

We’re in Brussels with Edwin Moses, the former CEO of one of the most successful platform companies in Europe, Ablynx, now part of Sanofi. We talk about how he feels 5 years after the exit from Ablynx and his lessons. We also talk about the parallels between industrial biotech, AI bio and cell therapy, and how a chairman can help CEOs grow.

💎 ABOUT THE SPEAKER
Edwin Moses is Chairman of Achilles Thx (cell therapy for solid tumors), Avantium (bioplastics) and LabGenius (AI biotech). He is the former CEO of one of the most successful platform companies in Europe, Ablynx, now part of Sanofi. I interviewed him back in 2018 when he sold the company.

📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/edwin-moses-biotech-platforms/



🔗 LINKS MENTIONED


Sanofi to acquire Ablynx for €3.9 Billion - https://www.sanofi.com/en/media-room/press-releases/2018/2018-01-29-07-19-03-1313306

Edwin Moses on stage in 2018 - https://www.youtube.com/watch?v=nWkd99rxVhc&t=802s&pp=ygUVZWR3aW4gbW9zZXMgbGFiaW90ZWNo

🫶 FOLLOW US
- Newsletter: http://eepurl.com/h_fnmH
- LinkedIn: https://www.linkedin.com/company/flot-bio/
- X (Twitter): https://x.com/FlotBio

🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.

⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!

🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

⏰ TIMESTAMPS

We’re in Copenhagen with Jens Nielsen, the CEO of BioInnovation Institute. We will talk about what works best to translate academic research in bio into innovation for humanity, especially how everything is connected. We also talk about how BII is solving some of the main challenges scientist entrepreneurs face and the drawbacks of Novo financing most of Denmark’s biotech ecosystem.

💎 ABOUT THE SPEAKER
Jens Nielsen is one of the best in this space in Europe. Not only is he the CEO of BII, he’s also a professor of systems biology at Chalmers University of Technology in Sweden, and is the most cited researcher in the field of metabolic engineering as well as industrial biotechnology. He’s the founder of the International Metabolic Engineering Society and has also founded many biotechs.

📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/jens-nielsen-translation-of-life-science-research/

🫶 FOLLOW US
- Newsletter: http://eepurl.com/h_fnmH
- LinkedIn: https://www.linkedin.com/company/flot-bio/
- X (Twitter): https://x.com/FlotBio

🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free.

⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!

🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

⏰ TIMESTAMPS
[00:00:00] Intro
[00:00:29] Welcome
[00:01:43] Translation of science
[00:08:48] Being flexible is key
[00:11:58] When to stop being flexible
[00:19:34] Listen to your gut
[00:22:38] The importance of network
[00:28:05] Entrepreneurial mindset recipe
[00:31:08] Role models
[00:32:38] Interaction with industry
[00:43:07] Results of BII
[00:54:14] How to be cost-effective in helping startups
[00:57:56] Novo Nordisk
[01:11:07] Closing the lab
[01:17:46] Thanks for listening

We’re in Amsterdam with Sander van Deventer, the CEO of VectorY. We will talk about VectorY and what’s missing in gene therapy.

💎 ABOUT THE SPEAKER
Sander has an impressive track record, being a professor, operational biotech founder and a VC. In 1998, he co-founded uniQure, which brought the first gene therapy to the market. He also co-founded the leading VC Forbion as well as Dezima. He is now building a new venture VectorY, again in gene therapy. I interviewed him in 2017 back at Labiotech so it’s great to catch up with him again.

📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/sander-van-deventer-gene-therapy/

🫶 FOLLOW US
- Newsletter: http://eepurl.com/h_fnmH
- LinkedIn: https://www.linkedin.com/company/flot-bio/
- X (Twitter): https://x.com/FlotBio

🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free.

⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!

🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

⏰ TIMESTAMPS

[00:00:00] Intro
[00:01:54] VectorY: Raising the largest Series A in 2023 in 🇪🇺
[00:05:01] What's coming for ALS
[00:07:50] How Vectorized Antibodies work
[00:17:57] New Vector (AAV) technologies
[00:22:55] The pipeline of VectorY
[00:27:22] Where VC money is moving to
[00:32:29] The Netherlands as a biotech cluster
[00:35:31] CRISPR approval and gene therapy reimbursement
[00:48:15] Where Sander came from
[00:56:14] How to have the energy to be a serial entrepreneur